Mechanisms of Resistance to PSMA Radioligand Therapy

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of California, San Francisco
Study ID
NCT05435495
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Single-photon emission computed tomography — PROCEDURE
    Imaging procedure
  • Blood Draw — PROCEDURE
    Blood draw for future research tests (45-60 mL).
  • Tumor Biopsy — PROCEDURE
    Guided biopsy of lesion

Study Details

This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.

Key Dates

Start date
Oct 21, 2021
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
125 participants (estimated)

Arms

  • Arm: Participants undergoing 177Lu-PSMA-617 treatment
    Participants undergoing PSMA targeted radioligand therapy with at least four cycles of treatment planned will undergo the following: SPECT/CTs will be performed 24 hours after the first treatment and after the fourth treatment, a tumor biopsy will be performed prior to the first 177Lu-PSMA radioligand therapy, a blood will be drawn prior to treatment for future research, and an optional tumor biopsy and blood draw for future research, may also be obtained at time of progression.

Primary Outcome Measure

Mean whole body tumor absorbed dose (WB Dose) across all metastatic lesions [ Time Frame: Up to 6 months ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
University of California, Los AngelesLos AngelesCalifornia90095
Johannes Czernin, MD (PRINCIPAL_INVESTIGATOR)
Matthew Rettig, MD (PRINCIPAL_INVESTIGATOR)
University of California, San FranciscoSan FranciscoCalifornia94143
Maya Aslam
[email protected]
415-514-8987
[email protected]
877-827-3222
Thomas Hope, MD (PRINCIPAL_INVESTIGATOR)
Memorial Sloan KetteringNew YorkNew York10065
Lisa Bodei, MD (PRINCIPAL_INVESTIGATOR)
Michael Morris, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
University of California, Los Angeles· Los Angeles, CAUniversity of California, San Francisco· San Francisco, CAMemorial Sloan Kettering· New York, NY

Related Studies